JAZZ - Health Canada approves Jazz Pharmaceuticals' Vyxeos to treat certain patients with leukemia

Health Canada has approved Jazz Pharmaceuticals' (JAZZ) Vyxeos for the treatment of certain adult patients with acute myeloid leukemia  ((AML)).The approval allows for the treatment of newly diagnosed therapy-related AML ((t-AML)) or AML with myelodysplasia-related changes ((AML-MRC)).AML, a cancer of the bone marrow and the blood, is considered a rare disease, and affects about 1,100 men and women in Canada annually.The approval of Vyxeos is based on results from a late-stage study of 309 adult patients, aged 60-75, with newly diagnosed t-AML or AML-MRC.The study met its primary endpoint as Vyxeos showed a superior improvement in overall survival compared to the current conventional treatment group.The median overall survival for the Vyxeos treatment group was 9.6 months compared with 6.0 months for the current conventional treatment group.

For further details see:

Health Canada approves Jazz Pharmaceuticals' Vyxeos to treat certain patients with leukemia